In vitro Studies of Mucoadhesiveness and Release of Nicotinamide Oral Gels Prepared from Bioadhesive Polymers

Authors: Sarunyoo Songkro, Naranut Rajatasereekul, Nipapat Cheewasrirungrueng

Abstract:

The aim of the present study was to evaluate the mucoadhesion and the release of nicotinamide gel formulations using in vitro methods. An agar plate technique was used to investigate the adhesiveness of the gels whereas a diffusion apparatus was employed to determine the release of nicotinamide from the gels. In this respect, 10% w/w nicotinamide gels containing bioadhesive polymers: Carbopol 934P (0.5-2% w/w), hydroxypropylmethyl cellulose (HPMC) (4-10% w/w), sodium carboxymethyl cellulose (SCMC) (4-6% w/w) and methylcellulose 4000 (MC) (3-5% w/w) were prepared. The gel formulations had pH values in the range of 7.14 - 8.17, which were considered appropriate to oral mucosa application. In general, the rank order of pH values appeared to be SCMC > MC4000 > HPMC > Carbopol 934P. Types and concentrations of polymers used somewhat affected the adhesiveness. It was found that anionic polymers (Carbopol 934 and SCMC) adhered more firmly to the agar plate than the neutral polymers (HPMC and MC 4000). The formulation containing 0.5% Carbopol 934P (F1) showed the highest release rate. With the exception of the formulation F1, the neutral polymers tended to give higher relate rates than the anionic polymers. For oral tissue treatment, the optimum has to be balanced between the residence time (adhesiveness) of the formulations and the release rate of the drug. The formulations containing the anionic polymers: Carbopol 934P or SCMC possessed suitable physical properties (appearance, pH and viscosity). In addition, for anionic polymer formulations, justifiable mucoadhesive properties and reasonable release rates of nicotinamide were achieved. Accordingly, these gel formulations may be applied for the treatment of oral mucosal lesions.

Keywords: Nicotinamide, bioadhesive polymer, mucoadhesiveness, release rate, gel.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1077062

References:

[1] A. H. Shojaei, "Buccal mucosa as a route for systemic drug delivery: a review," J. Pharm. Pharm. Sci., vol. 1, pp 15-30, Jan. 1998.
[2] D. N. Thorburn and M. M. Ferguson, "Topical corticosteroids and lesions of the oral mucosa," Adv. Drug Deliv. Rev., vol. 13, pp. 135- 149, Jan. 1994.
[3] C. S. Sweetman, Martindale: The Complete Drug Reference. 34 th ed. London: The Pharmaceutical Press, 2005, pp. 1441-1442.
[4] U. R. Hengge, T. Ruzicka, R. A. Schwartz, and M. J. Cork, "Adverse effects of topical glucocorticosteroids," J. Am. Acad. Dermatol., vol. 4, pp. 1-15, Jan. 2006.
[5] S. J. Sveinsson and W. P. Holbrook, "Oral mucosal adhesive ointment containing liposomal corticosteroid," Int. J. Pharm., vol. 95, pp.105-109, June 1993.
[6] N. Otte, C. Borelli, and H. C. Korting, "Nicotinamide-biologic actions of an emerging cosmetic ingredient." Int. J. Cos. Sci., vol. 27, pp. 255-261, Oct. 2005.
[7] N. M. Niren, "Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review," Cutis, vol. 77 (1 Suppl.), pp.11-16, Jan. 2006.
[8] Expert Group on Vitamins and Minerals. Safe Upper Levels for Vitamins and Minerals. United Kingdom: Food Standards Agency, 2003, pp. 52-61.
[9] J. I. Rader, R. J. Calvert, and J.N. Hathcock, "Hepatic toxicity of unmodified and time -release preparations of niacin," Am J. Med., vol. 92, pp. 77-81, Jan. 1992.
[10] A. R. Shalita, J. G. Smith, L. C. Parish, M. S. Sofman, and D. K. Chalker, "Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris," Int. J. Dermatol., vol. 34, pp. 434-437, June 1995.
[11] D. L. Bissett and J. E. Oblong, "Cosmeceutical vitamins: Vitamin B,". in Procedures in Cosmetic Dermatology Series: Cosmeceuticals, Z. D. Draelos, Ed. Philadelphia: Elsevir Saunders, 2005, pp. 57-62.
[12] T. Hakozaki, L. Minwalla, J. Zhuang, M. Chhoa, A. Matsubara, K. Miyamoto, A. Greatens, G. G. Hillebrand, D. L. Bissett, and R. E. Biossy., "The effect of nicotinamide on reducing cutaneous hyperpigmentation and suppression of melanosome transfer," Br. J. Dermatol., vol. 147, pp. 20-31, July 2002.
[13] F. C. Kull, Jr., and F. A. Voelker, "Method of promoting healing," U.S. Patent 4725609, Feb. 16, 1988.
[14] R. B. Gandhi and J. R. Robinson, "Oral cavity as a site for bioadhesive drug delivery," Adv. Drug Deliv. Rev., vol. 13, pp. 43-74, Jan. 1994.
[15] R. L. Dunn, "Polymeric matrices," in Polymeric Drugs and Drug Delivery Systems, R. L. Dunn, and R. M. Ottenbrite, Eds. Washington, DC: American Chemical Society, 1991, pp. 11-23.
[16] N. A. Peppas, P. Bures, W. Leobandung and H. Ichikawa, "Hydrogels in pharmaceutical formulations," Eur. J. Pharm. Biopharm., vol. 50, pp. 27- 46, July 2000.
[17] J. Y. Fang, Y. L. Leu, Y. Y. Wang, and Y. H. Tsai, "In vitro topical application and in vivo pharmacodynamic evaluation of nonivamide hydrogels using Wistar rat as an animal model," Eur. J. Pharm. Sci., vol. 15, pp. 417-423, June 2002.
[18] L. Shoufeng, L. Senshang, P.D. Bruce, L.M. Haresh, and W.C. Yie, "Effect of HPMC and carbopol on the release and floating properties of gastric floating drug delivery system using factorial design," Int. J. Pharm., vol. 253, pp. 13-22, Mar. 2003.
[19] A. A. Koffi, F. Agnely, G. Ponchel, and J.L. Grossiord, "Modulation of the rheological and mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended for the rectal administration of quinine," Eur. J. Pharm. Sci., vol. 27, pp. 328-335, Mar. 2006.
[20] F. Nakamura, R. Ohta, Y. Machida, and T. Nagai, "In vitro and in vivo nasal mucoadhesion of some water-soluble polymers," Int. J. Pharm., vol. 134, pp. 173-181, May 1996.
[21] C. M. Klech, "Gels and Jellies," in Encyclopedia of Pharmaceutical Technology, vol. 6, J. Swarbrick, and J. C. Boylan, Eds. New York: Marcel Dekker, Inc., 1992, pp. 415-439
[22] S. Ungphaiboon and Y. Maitani, "In vitro permeation studies of triamcinolone acetonide mouthwashes," Int. J. Pharm., vol. 220, pp. 111- 117, June 2001.
[23] W. I. Higuchi, "Diffusional models useful in biopharmaceutics: drug release rate processes," J. Pharm. Sci., vol. 56, pp. 315-324, 1967.
[24] D. J. Aframian, T. Davidowitz, and R. Benoliel, "The distribution of oral mucosal pH values in healthy saliva secretors," Oral Dis., vol 12, pp. 420-423, July 2006.
[25] C. Tas, C. K. Ozkan, A. Savaser, Y. Ozkan, U. Tasdemir, and H. Altunay, "Nasal absorption of metoclopramide from different Carbopol® 981 based formulations: In vitro, ex vivo and in vivo evaluation," Eur. J. Pharm. Biopharm., vol. 64, pp.246-254, Oct. 2006.
[26] C. Tas, Y. Ozkan, A. Savaser, and T. Baykara, "In vitro release studies of chlorpheniramine maleate from gels prepared by different cellulose derivatives," IL Farmaco., vol. 58, pp. 605-611, Aug. 2003.